Back to Newsroom
Back to Newsroom

Corporate News Blog - Cesca Therapeutics Announces Issuance of New Cellular Processing Patent

Monday, 31 July 2017 07:40 AM

Pro-Trader Daily

Topic:

Research Desk Line-up: IRadimed Post Earnings Coverage

LONDON, UK / ACCESSWIRE / July 31, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Cesca Therapeutics Inc. (NASDAQ: KOOL) ("Cesca"), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=KOOL. The Company, which is a market leader in automated cell processing, announced on July 28, 2017, that the US Patent and Trademark Office has awarded a new US Patent (the ‘394 patent'), entitled Cell Separation Devices, Systems, and Methods to SynGen, Inc., whose cell processing assets were acquired by ThermoGenesis Corp. on July 10, 2017. For immediate access to our complimentary reports, including today's coverage, register for free now at:

http://protraderdaily.com/register/

Discover more of our free reports coverage from other companies within the Medical Appliances & Equipment industry. Pro-TD has currently selected IRadimed Corporation (NASDAQ: IRMD) for due-diligence and potential coverage as the Company announced on July 28, 2017, its financial results for Q2 2017 which ended on June 30, 2017. Tune into our site to register for a free membership, and be among the early birds that get our report on IRadimed when we publish it.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on KOOL; also brushing on IRMD. Go directly to your stock of interest and access today's free coverage at:

http://protraderdaily.com/optin/?symbol=KOOL

http://protraderdaily.com/optin/?symbol=IRMD

ThermoGenesis Corp., a leader in developing and manufacturing automated blood and bone marrow processing systems, and companion disposable products, merged with TotipotentRX to form ThermoGenesis, changing its corporate name to Cesca Therapeutics Inc., on February 13, 2014.

‘394 Patent'

Automated Cellular Separation and BACS Processes - Cesca's ‘394 patent' covers a device and methodology for integrating automated cellular separation and buoyancy-activated cell sorting (BACS) processes. BACS employs microscopic bubbles to isolate a specific cell type from a complex mixture of cells, such as blood. The patent also permits the automated isolation of cells with low-density surface antigens, which was previously a major cellular manufacturing challenge.

Platform for Development of CAR-T and CAR-NK Therapeutics - The patent relates to the automated isolation of rare, therapeutically critical target cells from blood, bone marrow, leukapheresis product, and other cell sources while maintaining the viability of the cells under asceptic conditions. This advanced technology is part of Cesca's proprietary CAR-TXpress™ platform, an automated solution that isolates target cells using patented BACS technology. The CAR-TXpress™ system provides a comprehensive and commercially viable, automated cellular manufacturing and control (CMC) solution for the development of CAR-T and CAR-NK therapeutics.

Strengthens the Intellectual Property Position

Commenting on the issuance of the patent, Chris Xu, Cesca's Chief Executive Officer stated:

"This new patent issuance significantly strengthens the intellectual property position surrounding our proprietary automation technology which is core to our best-in-class ThermoGenesis portfolio of cell processing systems. Traditional cell processing methodologies, including those currently being implemented and used by leading CAR-T developers, are manual and time-consuming, presenting significant challenges to the future large-scale commercial feasibility of these revolutionary therapies."

He further added:

"Cesca's patented, automated cell processing systems provide greater cell yields and higher consistency in a fraction of the time, making them ideally suited to meet industry needs. The ability to leverage our technology to commercialize the BACS process is a milestone achievement for our company."

About Cesca Therapeutics Inc.

Founded in 1986, Cesca is a leading regenerative medicine company that develops, commercializes, and markets a range of automated technologies for cell-based therapeutics. The Company's device division, ThermoGenesis Corp., provides a full suite of solutions for automated clinical bio-banking, point-of-care applications, and automation for immuno-oncology. Cesca is an affiliate of the BoyaLife Group, a China-based industry research alliance encompassing top research institutions for stem cell and regenerative medicine. The Company is headquartered in Rancho Cordova, California.

Last Close Stock Review

On Friday, July 28, 2017, the stock closed the trading session at $3.85, surging 11.92% from its previous closing price of $3.44. A total volume of 3.19 million shares have exchanged hands, which was higher than the 3-month average volume of 37.82 thousand shares. Cesca Therapeutics' stock price surged 23.00% in the last one month, 24.60% in the past three months, and 30.07% in the previous six months. Furthermore, since the start of the year, shares of the Company have rallied 11.59%. The stock currently has a market cap of $34.11 million.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: [email protected]

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

Topic:
Back to newsroom
Back to Newsroom
Share by: